Kuros Biosciences AG
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CSBTF research report →
Companywww.kuros.ch
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems.
- CEO
- Christopher T. Fair
- IPO
- 2014
- Employees
- 122
- HQ
- Schlieren, CH
Price Chart
Valuation
- Market Cap
- $975.45M
- P/E
- 521.40
- P/S
- 6.63
- P/B
- 12.75
- EV/EBITDA
- 83.11
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 87.02%
- Op Margin
- 5.99%
- Net Margin
- 1.26%
- ROE
- 2.28%
- ROIC
- 4.04%
Growth & Income
- Revenue
- $121.36M · 60.62%
- Net Income
- $2.12M · 157.04%
- EPS
- $0.06 · 155.16%
- Op Income
- $7.33M
- FCF YoY
- -218.57%
Performance & Tape
- 52W High
- $42.81
- 52W Low
- $24.75
- 50D MA
- $27.91
- 200D MA
- $33.26
- Beta
- 0.70
- Avg Volume
- 181
Get TickerSpark's AI analysis on CSBTF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CSBTF Coverage
We haven't published any research on CSBTF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CSBTF Report →